- Home
- UBSI vs SYRE Comparison
UBSI vs SYRE Comparison
Compare UBSI & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UBSI | SYRE |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.9B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | UBSI | SYRE |
|---|---|---|
| Price | $43.58 | $71.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $43.17 | ★ $85.08 |
| AVG Volume (30 Days) | 725.3K | ★ 1.3M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 18.91 | N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $311,957,000.00 | N/A |
| Revenue This Year | $10.13 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | $13.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $34.10 | $12.29 |
| 52 Week High | $45.93 | $76.00 |
Technical Indicators
Market Signals| Indicator | UBSI | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 63.25 |
| Support Level | $43.21 | $30.39 |
| Resistance Level | $43.78 | $74.92 |
| Average True Range (ATR) | 0.85 | 4.21 |
| MACD | -0.13 | -0.75 |
| Stochastic Oscillator | 31.25 | 48.57 |
Price Performance
Historical ComparisonAbout UBSI United Bankshares Inc.
United Bankshares Inc is a financial holding company that provides banking services. The company operates in one segment: Community banking, which offers a full range-of-products and services through various delivery channels. Included among the banking products and services offered are the acceptance of deposits in checking, savings, time, and money market accounts; the making and servicing of personal, credit card, commercial, and floor plan loans; and the making of construction and real estate loans, as well as the origination and sale of residential mortgages in the secondary market. Also offered are trust and brokerage services, safe deposit boxes, and wire transfers.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.